Inhibition of Hec1 as a novel approach for treatment of primary liver cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 511-520

  Huang, Lynn Y L ^a   Chang, Chia Chi ^a   Lee, Ying Shuan ^b   Huang, Jiann Jyh ^b   Chuang, Shih Hsien ^b   Chang, Jia Ming ^b   Kao, Kuo Jang ^a   Lau, Gillian M G ^a   Tsai, Pei Yi ^b   Liu, Chia Wei ^b   Lin, Her Sheng ^b   Gish, Robert G ^a,c   Lau, Johnson Y N ^a  

^a Taivex Therapeutics Corporation   (Taiwan)

^b DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticancer drug; HCC; Mitosis; NDC80; Therapeutics

Indexed keywords

CELL PROTEIN; DOXORUBICIN; NDC80 COMPLEX; NEK2 PROTEIN; PACLITAXEL; PROTEIN INHIBITOR; SMC1A PROTEIN; SMC2 PROTEIN; SORAFENIB; TAI 95; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE EXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE HEC1; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907598099     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2540-7     Document Type: Article

References (34)

1. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE (2010) Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J hepatol 2(1):16-20. doi:10.4254/wjh.v2.i1.16
2. Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I, van Vlierberghe H, van den Bosch MA (2012) Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials 13(1):144. doi:10.1186/1745-6215-13-144
3. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J clin oncol off J Am Soc Clin Oncol 24(12):1898-1903. doi:10.1200/JCO.2005.04.9130 (Pubitemid 46638989)
4. Sacco R, Bargellini I, Ginanni B, Bertini M, Faggioni L, Federici G, Romano A, Bertoni M, Metrangolo S, Altomare E, Parisi G, Tumino E, Scaramuzzino A, Bresci G, Bartolozzi C (2012) Longterm results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev Anticancer Ther 12(7):869-875. doi:10.1586/era.12.58
5. Tanaka TU, Desai A (2008) Kinetochore-microtubule interactions: the means to the end. Curr Opin Cell Biol 20(1):53-63. doi:10.1016/j.ceb.2007.11.005
6. Ferretti C, Totta P, Fiore M, Mattiuzzo M, Schillaci T, Ricordy R, Di Leonardo A, Degrassi F (2010) Expression of the kinetochore protein Hec1 during the cell cycle in normal and cancer cells and its regulation by the pRb pathway. Cell Cycle 9(20):4174-4182
7. Chen Y, Riley DJ, Zheng L, Chen P-L, Lee W-H (2002) Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem 277(51):49408-49416. doi:10.1074/jbc. M207069200 (Pubitemid 36014374)
8. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH (2008) Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 68(20):8393-8399. doi:10.1158/0008-5472.CAN-08-1915
9. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R (2008) Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci USA 105(43):16719-16724. doi:10.1073/pnas. 0803504105
10. Qu Y, Li J, Cai Q, Liu B (2014) Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth. J Gastroenterol 49(3):408-418. doi:10.1007/s00535-013-0809-y
11. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, Ozturk M (1993) Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J Off Publ Fed Am Soc Exp Biol 7(14):1407-1413 (Pubitemid 23336171)
12. Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EH, Lee WH (2014) Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene. doi:10.1038/onc.2014.67
13. Huang LY, Lee YS, Huang JJ, Chang CC, Chang JM, Chuang SH, Kao KJ, Tsai YJ, Tsai PY, Liu CW, Lin HS, Lau JY (2014) Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1. J Exp clin Cancer Res CR 33:6. doi:10.1186/1756-9966-33-6
14. Lee YS, Chuang SH, Huang LY, Lai CL, Lin YH, Yang JY, Liu CW, Yang SC, Lin HS, Chang CC, Lai JY, Jian PS, Lam K, Chang JM, Lau JY, Huang JJ (2014) Discovery of 4-Aryl-N-aryl-carbonyl-2-aminothiazoles as Hec1/Nek2 Inhibitors. Part I: Optimization of in Vitro Potencies and Pharmacokinetic Properties. Journal of medicinal chemistry. doi:10.1021/jm401990s
15. Huang LY, Chang CC, Lee YS, Chang JM, Huang JJ, Chuang SH, Kao KJ, Lau GM, Tsai PY, Liu CW, Lin HS, Lau JY (2014) Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo. Mol Cancer Ther. doi:10.1158/1535-7163.MCT-13-0700
16. Wei R, Ngo B, Wu G, Lee WH (2011) Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 22(19):3584-3594. doi:10.1091/mbc.E11-01-0012
17. Zheng L, Chen Y, Lee WH (1999) Hec1p, an evolutionarily conserved coiled-coil protein, modulates chromosome segregation through interaction with SMC proteins. Mol Cell Biol 19(8):5417-5428 (Pubitemid 29339900)
18. Hasumura S, Sujino H, Nagamori S, Kameda H (1988) Establishment and characterization of a human hepatocellular carcinoma cell line JHH-4. Hum Cell 1(1):98-100
19. Homma S, Nagamori S, Fujise K, Hasumura S, Sujino H, Matsuura T, Shimizu K, Niiya M, Kameda H (1990) Establishment and characterization of a human hepatocellular carcinoma cell line JHH-7 producing alpha -fetoprotein and carcinoembryonic antigen-changes in secretion of AFP and CEA from JHH-7 cells after heat treatment. Hum Cell 3(2):152-157
20. Ku JL, Park JG (2005) Biology of SNU cell lines. Cancer Res Treat Off J Korean Cancer Assoc 37(1):1-19. doi:10.4143/crt.2005.37.1.1
21. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU et al (1995) Characterization of cell lines established from human hepatocellular carcinoma. Int J cancer J Int du Cancer 62(3):276-282
22. Chen Y, Riley DJ, Chen PL, Lee WH (1997) HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis. Mol Cell Biol 17(10):6049-6056 (Pubitemid 27411113)
23. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC (2003) TP53 and liver carcinogenesis. Hum Mutat 21(3):201-216. doi:10.1002/humu.10176 (Pubitemid 36292963)
24. Charette N, De Saeger C, Horsmans Y, Leclercq I, Starkel P (2013) Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis 4:e471. doi:10.1038/cddis.2012.200
25. Parekh P, Motiwale L, Naik N, Rao KV (2011) Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxic Pathol Off J Gesellschaft fur Toxikologische Pathologie 63(1-2):167-173. doi:10.1016/j.etp.2009.11.005
26. Li G, Zhang S, Fang H, Yan B, Zhao Y, Feng L, Ma X, Ye X (2013) Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1. Biochem Biophysi Res Commun 434(4):809-814. doi:10.1016/j.bbrc.2013.04.018
27. Sundin LJ, Guimaraes GJ, Deluca JG (2011) The NDC80 complex proteins Nuf2 and Hec1 make distinct contributions to kinetochore-microtubule attachment in mitosis. Mol Biol Cell 22(6):759-768. doi:10.1091/mbc.E10-08-0671
28. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P (2008) Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15(4):1008-1014. doi:10.1245/s10434- 007-9705-0
29. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM (2013) Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res CR 32(1):16. doi:10.1186/1756-9966-32-16
30. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M (2010) Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J cancer J Int du Cancer 126(9):2049-2066. doi:10.1002/ijc.24861
31. Chun E, Lee KY (2004) Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophysi Res Commun 315(3):771-779. doi:10.1016/j.bbrc.2004.01.118 (Pubitemid 38229409)
32. Takahashi M, Saito H, Atsukawa K, Ebinuma H, Okuyama T, Ishii H (2003) Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. Hepatol Res Off J Japan Soc Hepatol 25(2):192-201 (Pubitemid 36416669)
33. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL (2011) Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 337(1):155-161. doi:10.1124/jpet.110.175786
34. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19):1308-1324. doi:10.1093/jnci/djp280